Literature DB >> 22445469

Gastrointestinal symptoms predict peritonitis rates in CAPD patients.

Chun-Yan Su1, Juan Pei, Xin-Hong Lu, Wen Tang, Tao Wang.   

Abstract

OBJECTIVE: Peritonitis is still one of the major causes of peritoneal dialysis (PD) patients' dropout. In the present study, we analyzed the relationship between gastrointestinal (GI) problems and peritonitis in our CAPD patients.
METHODS: It is a prospective observational study. In December, 2008, 158 patients on continuous ambulatory peritoneal dialysis (CAPD) for more than 3 months from our PD unit were included in this study. A questionnaire was used to evaluate their GI symptoms score (GISS). All patients were followed up for 24 months or until they dropped out from our PD program. All peritonitis events were recorded.
RESULTS: The patients' PD duration was 22 (4 - 132) months before the study. During the 24 months follow-up, 37 patients dropped out. And 37 patients had 46 episodes of peritonitis (peritonitis group) whereas the other 121 patients did not have peritonitis (peritonitisfree group). The overall peritonitis rate was one episode per 75.87 patient months. The peritonitis free group had lower GISS (1.35 ± 1.94 vs. 2.95 ± 3.19, p = 0.006), higher albumin level and longer dialysis duration at baseline as compared to the peritonitis group. Multivariate Cox-regression analysis showed that only GISS (OR 1.206, 95% CI 1.093 - 1.330) and dialysis duration (OR 1.018, 95% CI 1.006 - 1.031) were the risk factors for the time to first peritonitis episodes during the follow-up. Further analysis identified 2 GISS components, belching and constipation, as the strongest predictors of peritonitis during the follow-up period (p < 0.005).
CONCLUSION: Our study showed that GI symptoms could predict peritonitis in CAPD patients. Prevention and treatment for GI problems may thus be helpful to decrease peritonitis rate.

Entities:  

Mesh:

Year:  2012        PMID: 22445469     DOI: 10.5414/cn107249

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  7 in total

Review 1.  Peritoneal dialysis-related infections recommendations: 2016 update. What is new?

Authors:  Vassilios Liakopoulos; Olga Nikitidou; Theofanis Kalathas; Stefanos Roumeliotis; Marios Salmas; Theodoros Eleftheriadis
Journal:  Int Urol Nephrol       Date:  2017-06-01       Impact factor: 2.370

2.  Astragaloside IV Alleviates Intestinal Barrier Dysfunction via the AKT-GSK3β-β-Catenin Pathway in Peritoneal Dialysis.

Authors:  Jiaqi He; Mengling Wang; Licai Yang; Hong Xin; Fan Bian; Gengru Jiang; Xuemei Zhang
Journal:  Front Pharmacol       Date:  2022-04-27       Impact factor: 5.988

3.  Influence of peritoneal dialysis catheter type on dislocations and laxative use: a retrospective observational study.

Authors:  Gianmarco Sabiu; Marco Heidempergher; Cristina De Salvo; Maria Antonietta Orani; Chiara Tricella; Maurizio Gallieni
Journal:  J Nephrol       Date:  2022-05-06       Impact factor: 4.393

4.  Low serum parathyroid hormone is a risk factor for peritonitis episodes in incident peritoneal dialysis patients: a retrospective study.

Authors:  Yuqi Yang; Jingjing Da; Yi Jiang; Jing Yuan; Yan Zha
Journal:  BMC Nephrol       Date:  2021-01-29       Impact factor: 2.388

Review 5.  ISPD Peritonitis Recommendations: 2016 Update on Prevention and Treatment.

Authors:  Philip Kam-Tao Li; Cheuk Chun Szeto; Beth Piraino; Javier de Arteaga; Stanley Fan; Ana E Figueiredo; Douglas N Fish; Eric Goffin; Yong-Lim Kim; William Salzer; Dirk G Struijk; Isaac Teitelbaum; David W Johnson
Journal:  Perit Dial Int       Date:  2016-06-09       Impact factor: 1.756

Review 6.  Constipation in CKD.

Authors:  Keiichi Sumida; Kunihiro Yamagata; Csaba P Kovesdy
Journal:  Kidney Int Rep       Date:  2019-11-13

7.  Serum Sphingosine-1-phosphate level and peritonitis in peritoneal dialysis patients.

Authors:  Qiong Bai; Hong-Xia Guo; Chun-Yan Su; Qing-Feng Han; Tao Wang; Wen Tang
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.